Brief communication: Effects of conditioned media from human platelet lysate cultured MSC on osteogenic cell differentiation in vitro

Siddharth Shanbhag¹,²*, Niyaz Al-Sharabi², Samih Mohamed-Ahmed², Reinhard Gruber³,⁴,⁵, Einar K. Kristoffersen¹,⁶ and Kamal Mustafa²

¹Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway, ²Center for Translational Oral Research, Department of Clinical Dentistry, Faculty of Medicine, University of Bergen, Bergen, Norway, ³Department of Oral Biology, University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria, ⁴Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland, ⁵Austrian Cluster for Tissue Regeneration, Vienna, Austria, ⁶Department of Clinical Sciences, Faculty of Medicine, University of Bergen, Bergen, Norway

Culturing mesenchymal stromal cells (MSC) in human platelet lysate (HPL) supplemented media can enhance their osteogenic differentiation potential. The objective of this study was to test the hypothesis that conditioned media (CM) derived from HPL-cultured MSC also have pro-osteogenic effects. Pooled CM was prepared from HPL-cultured human bone marrow MSC (BMSC) of multiple donors and applied on BMSC of different donors (than those used for CM preparation), with or without additional supplementation [HPL, fetal bovine serum (FBS)] and osteogenic stimulation. At various time-points, cell proliferation, alkaline phosphatase (ALP) activity, osteogenic gene expression and in vitro mineralization were assessed. BMSC in standard unstimulated growth media served as controls. After 3–7 days, CM alone did not promote BMSC proliferation or ALP activity; supplementation of CM with HPL slightly improved these effects. After 2 and 7 days, CM alone, but not CM supplemented with HPL, promoted osteogenic gene expression. After 14 days, only CM supplemented with FBS and osteogenic stimulants supported in vitro BMSC mineralization; CM alone and CM supplemented with HPL did not support mineralization, regardless of osteogenic stimulation. In summary, CM from HPL-cultured BMSC promoted osteogenic gene expression but not in vitro mineralization in allogeneic BMSC even when supplemented with HPL and/or osteogenic stimulants. Future studies should investigate the role and relevance of supplementation and osteogenic induction in in vitro assays using CM from MSC.

KEYWORDS
mesenchymal stromal cells, conditioned media, platelet lysate, bone tissue engineering, osteogenic differentiation
**Introduction**

Bone tissue engineering strategies are increasingly being used to overcome the limitations of autogenous bone grafts and existing biomaterials to reconstruct complex bone defects (Shanbhag et al., 2020a). Conventional tissue engineering strategies involve the transplantation of autologous adult mesenchymal stromal cells (MSC)—usually from the bone marrow (BMSC), in combination with biomaterial scaffolds and/or signaling molecules at bone defect sites. However, certain limitations of this approach have been discussed. Firstly, in a recent meta-analysis, we found the clinical evidence for the effectiveness of this strategy to be limited; the effect sizes of cell therapy over traditional GBR or grafting procedures were relatively small and mainly limited to studies of maxillary sinus augmentation (Shanbhag et al., 2019). Secondly, large scale translation of autologous cell therapy is limited by the need for expensive Good Manufacturing Practice (GMP) grade laboratories for *ex vivo* cell expansion for each patient/production. Thirdly, the traditional hypothesis that MSC exert their bioactivity *via* engraftment, differentiation, and replacement at injury sites, has in recent years been challenged by evidence of a predominantly paracrine mechanism of action (Haumer et al., 2018).

It is now widely believed that MSC exert their effects via the secretion of a wide range of bioactive factors, including soluble proteins (growth factors, cytokines, chemokines), nucleic acids and microparticles [extracellular vesicles (EV)] at or near sites of injury (Gnecchi et al., 2016). These factors in turn stimulate tissue-resident progenitor (osteogenesis), endothelial (angiogenesis) and immune cells (immune modulation), to drive subsequent regeneration processes. Moreover, pre-conditioning or “priming” of MSC with various stimulants (growth factors, inflammatory cytokines, etc.) may further enhance their paracrine activity and immunomodulatory potential (Ferreira et al., 2018). These findings provide the biological basis for the development of "cell-free" strategies, which exploit the secretome contained in MSC conditioned media (CM) for tissue regeneration. A major advantage of this strategy is the possibility to produce secretomes on a large scale from a single (or limited) cell expansion cycle(s), and to use these factors as "off-the-shelf" products. The preclinical efficacy of MSC secretomes/CM for bone regeneration has recently been summarized (Veronesi et al., 2018; Benavides-Castellanos et al., 2020).

A critical aspect in the clinical translation of cell therapies is the use of safe and standardized culture conditions resulting in safe-to-use cell constructs. Exclusion of animal-derived supplements, e.g., fetal bovine serum (FBS), in *ex vivo* culture systems is considered important to facilitate clinical translation of cell therapies and is also a recommendation by regulatory health authorities (Bieback et al., 2019). This consideration may also be extended to cell-derivatives such as CM. Pooled human platelet lysate (HPL) has been identified as the optimal “xeno-free” supplement for MSC culture, with particular benefits for MSC osteogenic differentiation (Fekete et al., 2012; Shanbhag et al., 2017). We have recently reported that HPL-cultured MSC demonstrate superior proliferation, osteogenic gene expression and *in vitro* mineralization vs. corresponding FBS-cultured cells (Shanbhag et al., 2020a; Shanbhag et al., 2020b). Indeed, the type of supplement used to culture MSC can influence the composition and efficacy of their CM (Madrigal et al., 2014; Nikolits et al., 2021). In context, few studies have assessed the composition of CM from HPL-cultured MSC or compared the composition of CM from HPL- vs. FBS-cultured MSC (Kehl et al., 2019; Palombella et al., 2020; Kim et al., 2021). Several growth factors related to wound healing, angiogenesis and extracellular matrix production were found to be more abundant in the CM of HPL- vs. FBS-cultured BMSC (Kim et al., 2021). Thus, based on these data, it is reasonable to hypothesize that CM from HPL-cultured MSC may be more enriched and potentially pro-osteogenic.

In the context of bone tissue engineering, the efficacy of CM is often studied *in vitro* via its effects on MSC proliferation and osteogenic differentiation. In this regard, previous studies reported that CM promotes MSC osteogenic differentiation; CM in most cases, was derived from FBS-cultured MSC and applied on cells of rodent origin (see review Veronesi et al., 2018). However, for *in vitro* assays, CM is usually supplemented with serum since CM alone does not support longer term cell culture. For differentiation assays, usually lasting 14–21 days, CM is supplemented with both serum and osteogenesis-inducing supplements, i.e., L-ascorbic acid 2-phosphate, dexamethasone and/or β glycerophosphate, in various concentrations (Brauer et al., 2016). To our knowledge, no studies have tested the effects of CM from HPL-cultured human MSC on the osteogenic differentiation of human MSC, which would more closely simulate a clinical scenario. As previously discussed, it is reasonable to hypothesize that CM from HPL-cultured MSC may have pro-osteogenic effects. Thus, the main objective of this preliminary study was to investigate the effects of pooled CM derived from HPL-cultured human BMSC of multiple donors on the *in vitro* proliferation and osteogenic differentiation of allogeneic (different donor) BMSC. A secondary objective was to assess the need for additional supplementation and/or osteogenic stimulation in the *in vitro* assays.

**Methods**

**Cell culture**

The use of human cells and tissues was approved by the Regional Committees for Medical Research Ethics (REK) in Norway (2013-1248/REK-sør-est and 2016-1266/REK-nord). Bone marrow specimens were obtained following parental
consent from five independent donors (2 females and 3 males; 8–10 years) undergoing reconstructive surgery at the Department of Plastic Surgery, Haukeland University Hospital, Bergen, Norway; BMSC were isolated and expanded following previous protocols (Shanbhag et al., 2020b). Briefly, cells were cultured in T75 or T175 flasks (Thermo Fisher Scientific, Carlsbad, CA, United States) using sterile filtered growth media (GM) comprising of Dulbecco’s Modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, United States) supplemented with 5% (v/v) pooled human platelet lysate (HPL; Bergenlys, Bergen, Norway), 1% (v/v) penicillin/streptomycin (GE Healthcare, South Logan, UT, United States) and 1 IU/ml heparin (Leo Pharma AS, Lysaker, Norway). HPL was produced ‘in-house’ as described elsewhere (Shanbhag et al., 2020b). Cells were sub-cultured and expanded under standard incubation, i.e., 37°C and 5% CO2, according to a clinically validated protocol with a seeding density of 4000 cells/cm² (Rojewski et al., 2019). Passage 1 (p1) and 2 (p2) BMSC were characterized based on immunophenotype and multi-lineage differentiation potential as previously reported (Shanbhag et al., 2020b), and used for CM preparation. In indicated experiments, BMSC from two separate donors (different from those used for CM preparation) were used to study the paracrine effects of CM. BMSC (p2) were seeded in 12-well plates (4000 cells/cm²) and exposed to CM for various durations in proliferation and differentiation assays. Cell attachment and morphology were regularly monitored under a light microscope (Nikon Eclipse TS100, Tokyo, Japan).

Conditioned media preparation

CM was prepared from BMSC of three independent donors, as previously described (Al-Sharabi et al., 2017). Briefly, p1 and p2 BMSC were expanded in T175 flasks in GM until 70%–80% confluency under standard incubation. At this point, cells were washed three times with phosphate-buffered saline (PBS; Invitrogen) and then cultured in plain DMEM (without HPL or antibiotics) for another 48 h. After 48 h, CM from p1 and p2 BMSC from each of the three donors was collected, pooled, and centrifuged at 4000 × g for 10 min to remove any debris. The supernatant was aliquoted and stored at −80°C. For all experiments, CM from −80°C storage was thawed overnight at 4°C and sterile filtered (0.2 μm) before use.

DNA quantification and alkaline phosphatase activity assays

BMSC were seeded in 24-well plates at a density of 4000 cells/cm² and cultured in GM. After 24 h, corresponding wells were washed with PBS and exposed to CM or CM-HPL (1% HPL); the concentration of HPL was adjusted in comparison to GM (5% HPL) to avoid overconfluence after 24 h. After 3 and 7 days, cells were lysed in 0.1% Triton X-100 (Sigma Aldrich) and DNA quantification and ALP activity assay were performed using the Quant-IT® PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific) and SIGMAFAST BCIP/NBT assay (Sigma Aldrich), respectively, according to manufacturers’ instructions. DNA concentrations (ng/ml), calculated based on known standards, were used to normalize ALP activity of the corresponding cell-lysates.

Gene expression analysis

Expressions of osteogenesis-related genes (Table 1) were assessed after 2 and 7 days via quantitative real-time polymerase chain reaction (qPCR) using TaqMan® real-time PCR assays (Thermo Scientific). BMSC in GM were seeded in 12-well plates; after 24 h, corresponding wells were washed with PBS and exposed to different media formulations: GM, CM alone (CM) and CM supplemented with 5% HPL (CM-PL). RNA extraction and cDNA synthesis were performed as previously described (Mohamed-Ahmed et al., 2018) and expressions of genes of interest were normalized to that of a reference gene—glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data were analyzed by the ΔΔCt method and results are presented as fold changes relative to the reference group (GM) on a log(2)-transformed scale.

In vitro mineralization assay

In vitro mineralization was assessed using the Alizarin red-S assay. BMSC in GM were seeded in 12-well plates; after 24 h, corresponding wells were washed with PBS and exposed to different media formulations with osteogenic induction supplements: growth media (GM+), CM (CM+) and CM with 5% HPL (CM-PL+). To induce osteogenic differentiation, media were supplemented with final

### Table 1 Real time qPCR primers.

| Gene (human) | TaqMan® assay ID | Amplicon length |
|--------------|-----------------|-----------------|
| References   |                 |                 |
| GAPDH        | Hs02758991_g1   | 93              |
| Osteogenesis-related |     |                 |
| RUNX2        | Hs01047973_m1   | 86              |
| COL1A2       | Hs00164099_m1   | 68              |
| OPN (SPP1)   | Hs00959010_m1   | 84              |
| OCN (BGLAP)  | Hs01587814_g1   | 138             |

GAPDH glyceraldehyde 3-phosphate dehydrogenase, RUNX2 runt-related transcription factor 2, COL1A2 Collagen type 1 alpha 2, OPN/SPP1 osteopontin, OCN/BGLAP osteocalcin.
concentrations of 0.05 mM L-ascorbic acid 2-phosphate, 
10 nM dexamethasone and 10 mM β glycerophosphate (all 
from Sigma-Aldrich, St. Louis, MO, United States). 
Additionally, the following groups were included: CM 
supplemented with 2.5% HPL and osteogenic supplements 
and CM supplemented with 10% FBS and osteogenic 
supplements (CM-FBS+). After 14 days, formation of 
extracellular calcium deposits was assessed 
via Alizarin red S staining, as previously described (Mohamed-Ahmed et al., 
2018). Briefly, after fixation with 4% paraformaldehyde, cells 
were stained with 2% Alizarin red S solution (Sigma Aldrich) 
for 30 min at RT, then washed and dried, before images were 
acquired.

**Results**

Conditioned media supplemented with platelet lysate did not enhance cell proliferation

The *in vitro* paracrine effects of CM were evaluated via proliferation and ALP activity assays using BMSC from two independent donors. DNA content of BMSC was lower in CM vs. GM (5% HPL) after 3 (\(p < 0.001\)) and 7 days (\(p > 0.05\)); supplementation of CM with 1% HPL did not attenuate this difference at 3 days (Figures 1A,B). A similar trend was observed for ALP activity between the groups, although without statistical significance (Figure 1B).

Conditioned media supplemented with platelet lysate did not enhance osteogenic gene expression

After 2 d, compared to the reference group (GM), expressions of selected osteogenesis related genes, i.e., runt-related transcription factor 2 (RUNX2), collagen type 1A (COL1A), and osteopontin (SPP1/OPN), were significantly upregulated in BMSC exposed to CM alone after 2 and 7 days (\(p < 0.05\) for all genes; Figures 2A,B). In particular, expression of SPP1/OPN was remarkably upregulated in CM. Expression of
osteocalcin (BGLAP/OCN) was upregulated only after 7 days. When CM was supplemented with HPL (CM-PL), gene expression was either unchanged or downregulated compared to standard GM after 2 days. After 7 days, expressions of SPP1 and BGLAP were upregulated also in CM-PL (Figure 2B).

**Conditioned media supplemented with platelet lysate did not promote in vitro mineralization**

Initially, for the in vitro mineralization assay, BMSC were exposed to CM alone or CM supplemented 5% HPL, both with osteogenic stimulants. After 14 days, no mineralization was observed in any of the test groups (Figure 3). Reduction of HPL concentration (from 5% to 2.5%) did not affect the results (data not shown). However, supplementation of CM with 10% FBS (CM-FBS+) revealed in vitro mineralization of BMSC comparable to the positive GM control (Figure 3).

**Discussion**

Since HPL-cultured MSC demonstrate enhanced osteogenic differentiation and the CM of HPL-cultured MSC is more enriched than their FBS-cultured counterparts, the present study hypothesized that the CM of HPL-cultured BMSC has pro-osteogenic effects, i.e., the use of such CM could possibly reduce the need for additional serum/supplementation and/or osteogenic stimulation. Although previous studies have reported that CM promotes MSC osteogenic differentiation (Veronesi et al., 2018; Zhong et al., 2019), these have mainly assessed the effects of CM derived from FBS-cultured cells on MSC of non-human origin. Thus, little is known about the effects of CM from HPL-cultured MSC on allogeneic MSC of human origin. Such an in vitro setup would more closely simulate a clinical scenario of CM application, since: 1) current regulations recommend substitution of animal derivatives such as FBS in clinical-grade MSC cultures; and 2) CM would most likely be used as an allogeneic (pooled from multiple donors) "off-the-
The objective of this preliminary study was to investigate the effects of CM derived from HPL-cultured MSC (pooled CM from multiple donors) on the in vitro osteogenic differentiation of allogeneic (different donors) human MSC. The main findings were that: 1) CM alone promoted osteogenic gene expression, but not in vitro mineralization of BMSC, and 2) CM supplemented with HPL promoted neither osteogenic gene expression nor in vitro mineralization of BMSC.

In the present study, we investigated the influence of CM supplemented with different concentrations of HPL on the in vitro proliferation and osteogenic differentiation of BMSC. We observed that pure CM (without HPL) did not have positive effects on BMSC proliferation and in vitro mineralization, despite promoting significant upregulation of several osteogenesis-related genes. In previous studies, we showed that HPL-cultured MSC have an enhanced capacity for osteogenic differentiation (Shanbhag et al., 2020a; Shanbhag et al., 2020b). Therefore, we hypothesized that the secretomes of HPL-cultured BMSC (contained in CM) might have a stimulatory effect on cellular metabolic activity and osteogenic differentiation. However, based on the results herein, it seems that CM alone without added supplements (HPL/FBS) might impair the cultured BMSC via nutrient deprivation, thus reducing their metabolic activity and functions (Nuschke et al., 2016). It has also been reported that the “serum starvation” method used to collect CM might be associated with the lower content of the specific growth factors with metabolic activity in CM, e.g., hepatocyte growth factor (HGF), brain-derived neurotrophic factor (BDNF), and fibroblast growth factor 2 (FGF-2) (Petrenko et al., 2020). Further investigations to determine the effects of collection methods on the composition and concentrations of secreted molecules in CM are needed.

Cell metabolism and survival are controlled by the action of growth factors and cytokines through inhibition of apoptosis or promotion of cell survival. In previous studies, we have shown that CM from FBS-cultured BMSC contains several growth factors and cytokines with antiapoptotic and antioxidant properties, including platelet-derived growth factor (PDGF) and vascular endothelial growth factor A (VEGFA), and enhances in vitro osteogenic differentiation of MSC (Al-Sharabi et al., 2014; Al-Sharabi et al., 2016; Saleem et al., 2021). In context, HPL also contains several growth factors and cytokines, including PDGF, epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), FGF2, stem cell-growth factor-beta (SCGF), interleukin (IL)-1β, IL-2, -6, -10, -12p70, and IL-17A, tumor necrosis factor (TNF)-α and interferon (IFN) (Cañas-Arboleda et al., 2020; Shanbhag et al., 2020a). Therefore, it is reasonable to postulate that CM of HPL-cultured MSC would be correspondingly more enriched. Indeed, in a recent study, the concentrations of important growth factors such as VEGF, TGF-β1, and HGF were found to be significantly greater in the CM of HPL- vs. FBS-cultured MSC (Kim et al., 2021). However, we found that proliferation and osteogenic differentiation rates were insufficient in BMSC treated with 5% vs. 1% HPL-supplemented CM; a 5% concentration was selected based on current recommendations for HPL supplementation for ex vivo MSC expansion (Becherucci et al., 2018).

Regarding osteogenic differentiation, previous studies have reported that CM increased osteogenic differentiation and mineralization of MSC in a paracrine manner (Ogata et al., 2015; Zhong et al., 2019). However, most studies have not...
adequately addressed whether CM alone exerts this effect or whether the addition of FBS or HPL, with or without osteogenic supplements, is necessary. Such information would be important to standardize experimental setups and compare the results across different in vitro studies. In the present study, we found that pure CM stimulates neither ALP activity nor in vitro mineralization, as detected by Alizarin red staining. This was in line with a study conducted to evaluate proliferation and differentiation of osteoblasts under the induction of different concentrations of CM (Sun et al., 2012). When 1% HPL was added to CM, a slight improvement in ALP activity was detected although this was not equivalent to the control, i.e., GM containing 5% HPL. CM also promoted the expression of osteogenesis-related genes in BMSC, although this effect appears to be insufficient to stimulate in vitro mineralization, as no mineralization nodules were detected after 14 days. Thus, despite CM-induced gene upregulation in BMSC (without osteogenic supplementation), the impairment in promoting mineralization (with or without osteogenic supplementation) potentially reflects the safety of using BMSC as sources for CM production for different applications rather than specifically for bone regeneration.

In the context of osteogenic differentiation, we have previously reported that HPL supplementation alone (vs. FBS) enhances the expression of osteogenesis-related genes in MSC, suggesting particular benefits of HPL-supplemented MSC expansion for bone tissue engineering (Shanbhag et al., 2020a). Indeed, in the present study, exposure to CM resulted in an upregulation of osteogenic genes which was greater than that of HPL supplementation. However, the combination of HPL and CM did not exert a synergistic effect in terms of BMSC gene expression. This might indicate that a certain concentration of HPL together with CM might only allow the maintenance of the original microenvironment in BMSC, possibly via reduction of overexposure to cytokines and other stimulatory factors (Kandoi et al., 2018). On the contrary, the combination of CM and HPL may have antagonistic effects, which may distort the positive biological activity of CM. Therefore, future molecular research is warranted to study the effects of different combinational ratios of CM and HPL in vitro osteogenic differentiation of MSC (Aghamohamadi et al., 2020).

Moreover, while the present study focused on osteogenic stimulatory capacity, other pathways of CM bioactivity, particularly angiogenesis (Quade et al., 2020) and immune-modulation (Jin et al., 2022), are also highly relevant for bone regeneration.

Some limitations of the present preliminary study must be acknowledged. The objective herein was to test the hypothesis that CM from HPL-cultured MSC may have pro-osteogenic effects, and not to compare per se CM from HPL- vs. FBS-cultured MSC or the osteogenic effects of CM supplemented with HPL vs. FBS. Therefore, we did not include FBS supplemented CM as a control group in all experiments, but only in the in vitro mineralization assay. Secondly, although the CM used herein was produced and pooled from multiple BMSC donors (n = 3), which is clinically relevant in terms of scaling up production and minimizing individual donor variations, the number of allogeneic BMSC donors for the in vitro assays was limited (n = 2). It is well known that BMSC may demonstrate significant donor-related variations in their growth and differentiation potential (Al-Sharabi et al., 2017) and therefore, the experiments should be repeated with BMSC from additional donors to validate the findings. Lastly, in this preliminary study, we did not perform any mechanistic assays, e.g., identification of specific signaling pathways, to determine the molecular basis for reduced mineralization in CM, with or without additional supplements. This would be relevant mainly for future in vitro assessments of MSC responses to CM to potentially predict (within the limitations of in vitro models) the in vivo effects of CM for bone regeneration.

Clear descriptions of in vitro experimental setups, i.e., addition of serum/supplements and osteogenic stimulants, in future studies of CM efficacy are warranted to allow standardization and comparison of data.

### Conclusion

In summary, pooled CM from HPL-cultured human BMSC promoted osteogenic gene expression but not in vitro mineralization in allogeneic BMSC, even when supplemented with HPL and/or osteogenic stimulants. The role and relevance of CM supplementation and osteogenic stimulation in in vitro assays should be investigated in future studies to better understand the underlying molecular mechanisms and allow standardized comparisons of results.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

### Ethical statement

The use of human cells and tissues was approved by the Regional Committees for Medical Research Ethics (REK) in Norway (2013-1248/REK-sør-øst and 2016-1266/REK-nord).

### Author contributions

SS and NA-S conceived and designed the study. SS performed the experiments, data collection, data analysis and drafted the manuscript. NA-S and SM-A assisted with experiments, sample preparation, data collection, data analysis/interpretation and/or drafting the manuscript. RG,
EK, and KM assisted with data analysis/interpretation, drafting the manuscript and funding acquisition. All authors read and approved the final version of the manuscript.

Funding

This work was supported by the Osteology Foundation, Switzerland (18-152), Helse Vest Research Funding, Norway (F-12124), and Trond Mohn Foundation, Norway (BFS2018TMT10).

Acknowledgments

We thank the Bloodbank at Haukeland University Hospital for assistance with HPL production.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Aghamohamadi, Z., Kadkhodazadeh, M., Torshabi, M., and Tabatabaiei, F. (2020). A compound of concentrated growth factor and periodontal ligament stem cell-derived conditioned medium. Tissue Cell 65, 101373. doi:10.1016/j.tice.2020.101373

Al-Sharabi, N., Mustafa, M., Ueda, M., Xue, Y., Mustafa, K., and Fristad, I. (2017). Conditioned medium from human bone marrow stromal cells attenuates initial inflammatory reactions in dental pulp tissue. Dent. Traumatol. 33 (1), 19–26. doi:10.1111/ded.12277

Al-Sharabi, N., Yao, X., Fujio, M., Ueda, M., Gjerde, C., Mustafa, K., et al. (2014). Bone marrow stromal cell paracrine factors direct osteo/odontogenic differentiation of dental pulp cells. Tissue engineering Part A 20 (21–22), 3063–3072. doi:10.1089/ten.TEA.2013.0718

Al-Sharabi, N., Yao, X., Ueda, M., Mustafa, K., and Fristad, I. (2016). Influence of bone marrow stromal cell secreted molecules on pulp and periodontal healing in replanted immature rat molars. Dent. Traumatol. 32 (3), 231–239. doi:10.1111/ded.12246

Becherucci, V., Piccini, L., Casamassima, S., Biun, S., Gori, V., Gentile, F., et al. (2018). Human platelet lysate in mesenchymal stem cell expansion according to a GMP grade protocol: A cell factory experience. Stem Cell Res. Ther. 9 (1), 124. doi:10.1186/s13287-018-0868-9

Benavides-Castellanos, M. P., Garzon-Orjuela, N., and Linero, I. (2020). Effectiveness of mesenchymal and mesenchymal stem cell-conditioned medium in bone regeneration in animal and human models: A systematic review and meta-analysis. Cell Regen. 9 (1), 5. doi:10.1186/s13161-020-00047-3

Bieback, K., Fernandez-Munon, B., Pati, S., and Schäfer, R. (2019). Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AAB and the, international society for cell & gene therapy. Transfusion 59, 3448–3460. doi:10.1111/trf.15483

Brauer, A., Pohlemann, T., and Metzger, W. (2016). Osteogenetic differentiation of immature osteoblasts: Interplay of cell culture media and supplements. Biotech. Histochem. 91 (3), 161–169. doi:10.1007/s10520-015-1100-2

Cañas-Arboleda, M., Beltrán, K., Medina, C., Camacho, B., and Salguero, G. (2020). Human platelet lysate supports efficient expansion and stability of wharton’s jelly mesenchymal stromal cells via active uptake and release of soluble regenerative factors. Int. J. Mol. Sci. 21, 6284. doi:10.3390/ijms21176284

Fekete, N., Gadegrø, M., Furst, D., Maurer, C., Dausend, J., Fleury-Cappellesso, S., et al. (2012). Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stem cells: Production process, content and identification of active components. Cytotherapy 14 (5), 540–554. doi:10.1016/j.jcyt.2011.12.019

Ferreira, J. R., Tixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., and Gonçalves, R. M. (2018). Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. Front. Immunol. 9, 2837. doi:10.3389/fimmu.2018.02837

Gnecci, M., Danieli, P., Malpasso, G., and Ciaffreda, M. C. (2016). Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods Mol. Biol. 1416, 123–146. doi:10.1007/978-1-4939-3584-0_7

Hauser, A., Bouringe, P. E., Occhetta, P., Born, G., Tasso, R., and Martin, I. (2018). Delivery of cellular factors to regulate bone healing. Adv. Drug Deliv. Rev. 129, 285–294. doi:10.1016/j.addr.2018.01.010

Jin, Q. H., Kim, H. K., Na, J. Y., Jin, C., Seon, J. K., Kim, H. K., et al. (2022). Anti-inflammatory effects of mesenchymal stem cell-conditioned media inhibited macrophages activation in vitro. Sci. Rep. 12, 4754. doi:10.1038/s41598-022-08398-4

Kandori, S., Praveen.kumar, L., Patra, B., Vidyasekar, P., Sivanesan, D., Vijayalakshmi, S., et al. (2018). Evaluation of platelet lysate as a substitute for FBS in explant and enzymatic isolation methods of human umbilical cord MSCs. Sci. Rep. 8 (1), 12439. doi:10.1038/s41598-018-30772-4

Kehl, D., Generali, M., Mallone, A., Heller, M., Uldry, A. C., Cheng, P., et al. (2019). Proteomic analysis of human mesenchymal stromal cell secretomes: A systematic comparison of the angiogenic potential. npg Regen. Med. 4, 8. doi:10.1038/s41536-019-0070-y

Kim, S. N. Lee, C. J., Nam, J., Choi, B., Chung, E., and Song, S. U. (2021). The effects of human bone marrow-derived mesenchymal stem cell conditioned media produced with fetal bovine serum or human platelet lysate on skin rejuvenation healing in vitro. Stem Cell Res. Ther. 12, 115. doi:10.1186/s13287-011-0091-4

Koon, K. S., Fristad, I., Lin, S. A., Suliman, S., Mustafa, K., Vindenes, H., et al. (2018). Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. Stem Cell Res. Ther. 9 (1), 168. doi:10.1186/s13287-018-0914-1

Kočott, J., Nebel, S., Egger, D., Kress, S., and Kasper, C. (2021). Towards physiologic culture approaches to improve standard cultivation of mesenchymal stem cells. Cells 10 (4), 886. doi:10.3390/cells10040886

Nuschke, A., Rodrigues, M., Wells, A. W., Sykowskii, K., and Wells, A. (2016). Mesenchymal stem cells/multipotent stromal cells (MSCs) are glycolytic and thus glucose is a limiting factor of in vitro models of MSC starvation. Stem Cell Res. Ther. 7 (1), 179. doi:10.1186/s13287-016-0436-7

Ogata, K., Katagiri, W., Osugi, M., Kawai, T., Sugimura, Y., Hibi, H., et al. (2015). Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model. Bone. 74, 95–105. doi:10.1016/j.bone.2015.01.011

Palombella, S., Guotto, M., Higgins, G. C., Applegate, L. L., Raffoul, W., Cherubino, M., et al. (2020). Human platelet lysate as a potential clinical-translatable supplement to support the neutrophopic properties of human adipose-derived stem cells. Stem Cell Res. Ther. 11 (1), 432. doi:10.1186/s13287-020-01949-4
